NK cells from AML patients consistently exhibit decreased cytotoxic receptor expression (particularly NKp30, NKp44, NKp46, and DNAM-1) and decreased cytotoxicity compared to NK cells from healthy donors (58–60). This evidence concerns the gene CD226 and acute myeloid leukemia.